Harmony Biosciences Holdings, Inc. (HRMY)

From the record

Harmony Biosciences Holdings, Inc.'s filings since 2020 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

Harmony Biosciences Holdings, Inc.'s 7 filed years say what it did: revenue went from $6 million in fiscal 2019 to $868 million in fiscal 2025, up 129.1% a year; it rose in 6 of 6 years; it never fell from a peak; net income was positive in 5 of 7 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2025-12-31, Harmony Biosciences Holdings, Inc.'s diluted share count shrank about 1.4% a year, and dividends and buybacks returned about 13% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 13 sales (6 under scheduled 10b5-1 plans) and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2025-12-31, Harmony Biosciences Holdings, Inc. earned about 18 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 53 cents per dollar of everything the company owns. Leverage: it owed about 32 cents per dollar of assets, and net share issuance: its share count grew 1.2% over the year (the filed statements).

From the record

Harmony Biosciences Holdings, Inc.'s standing among 315 graded names in its industry family: revenue of $868 million in fiscal 2025 ranks in the top 13% by size; a net margin of 18.3% ranks in the top 12%; revenue growth of 25.6% a year over the last 3 filed years ranks in the top 34% (its annual reports).

From the record

Harmony Biosciences Holdings, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dayno, Jeffrey M. (PRESIDENT, CEO, as filed), filing under that title since 2023-05-30, 3.5 years (bottom 37% of its family); the 16 officers and directors filing in the last fifteen months have been on the record a median of 4 years (bottom 24%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 16 people in charge now (bottom 38%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Harmony Biosciences Holdings, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $753 million against debt of $144 million leaves 47.9% of its assets as net cash, top 34% of its family; cash from operations less capital spending is 40.1% of revenue (top 5%); a gross margin of 77.2% (top 39%); research spending of 21.8% of revenue (bottom 28%) (its annual report).

From the record

Harmony Biosciences Holdings, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 25.6% a year over the last three filed years against 129.1% over all 7, slowing (bottom 3% of its family); the newest year grew 21.5% (top 37%); research spending grew 38.8% a year (top 12%); capital spending grew 21.7% a year (top 24%) (its annual reports). Harmony Biosciences Holdings, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

From the record

Harmony Biosciences Holdings, Inc.'s newest year against its own record: revenue of $868 million in fiscal 2025 came in 4.9% below the $913 million its prior three years' pace pointed to (bottom 44% of its family); net income of $159 million against a prior three-year average of $152 million (bottom 43%); a net margin of 18.3% against 28% before (bottom 30%) (its annual reports).